Clinical Trial Update: A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias [Phase 1]

View source ↗

Summary

This is a Phase I clinical trial evaluating a triple combination of Ziftomenib, Venetoclax, and Azacitidine in pediatric patients with relapsed or refractory ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)
• Ziftomenib (ziftomenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Refractory Acute Leukemia, Pediatric Relapsed | Phase 1 | Status: RECRUITING